Preliminary results of a phase I, first-in-human, dose escalation study of IMM2902 in patients with HER2-expressing advanced solid tumors

被引：0
|
作者：
Meng, Yanchun
Zhang, Jian
Zhao, Chuanhua
Cheng, Ying
Zhu, Liming
Song, Zhengbo
Xu, Nong
Wang, Zhen
Wang, Yanping
Du, Yiqun
Jing, Deqiang
Chen, Dinglu
Qu, Qiaofeng
Zhao, Xiwen
Li, Wei
Lu, Qiying
Tian, Wenzhi
Xu, Jianming
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Phase Clin Trial Ctr 1, Shanghai, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[3] Sch Med, Beijing, Peoples R China
[4] Jilin Canc Hosp, Changchun, Peoples R China
[5] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China
[6] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[7] Linyi Canc Hosp, Linyi, Shandong, Peoples R China
[8] ImmuneOnco Biopharmaceut Shanghai Inc, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15185
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors
    Tabernero, Josep
    Dirix, Luc
    Schoffski, Patrick
    Cervantes, Andres
    Antonio Lopez-Martin, Jose
    Capdevila, Jaume
    van Beijsterveldt, Ludy
    Platero, Suso
    Hall, Brett
    Yuan, Zhilong
    Knoblauch, Roland
    Zhuang, Sen Hong
    CLINICAL CANCER RESEARCH, 2011, 17 (19) : 6313 - 6321
  • [32] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
    Elena Elez
    Carlos Gomez-Roca
    Arturo Soto Matos-Pita
    Guillem Argiles
    Thibaud Valentin
    Cinthya Coronado
    Jorge Iglesias
    Teresa Macarulla
    Sarah Betrian
    Salvador Fudio
    Katrin Zaragoza
    Josep Tabernero
    Jean-Pierre Delord
    Investigational New Drugs, 2019, 37 : 674 - 683
  • [33] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
    Elez, Elena
    Gomez-Roca, Carlos
    Soto Matos-Pita, Arturo
    Argiles, Guillem
    Valentin, Thibaud
    Coronado, Cinthya
    Iglesias, Jorge
    Macarulla, Teresa
    Betrian, Sarah
    Fudio, Salvador
    Zaragoza, Katrin
    Tabernero, Josep
    Delord, Jean-Pierre
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 674 - 683
  • [34] Phase I study of GQ1005, a new generation HER2-ADC, in patients with HER2-expressing and HER2 mutated advanced solid tumors
    Zhou, Caicun
    Yang, Bo
    Deng, Ting
    Wang, Biyun
    Zhang, Jian
    Sun, Yuping
    Wang, Linlin
    Yang, Hongwei
    Wang, Jingfen
    Li, Wei
    Song, Qi
    Yang, Yuchong
    CANCER RESEARCH, 2024, 84 (07)
  • [35] Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.
    Voss, Martin Henner
    Hierro, Cinta
    Heist, Rebecca Suk
    Cleary, James M.
    Meric-Bernstam, Funda
    Gandhi, Leena
    Ishii, Nobuya
    Kirpicheva, Yulia
    Nicolas-Metral, Valerie
    Pokorska-Bocci, Anna
    Purcea, Daniela
    Vaslin, Anne
    Moulon, Corinne
    Zanna, Claudio
    Flaherty, Keith
    Tabernero, Josep
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] First-in-human dose escalation study of oral ONC201 in advanced solid tumors.
    Stein, Mark N.
    Mayer, Tina M.
    Moss, Rebecca Anne
    Silk, Ann W.
    Chan, Nancy
    Haffty, Bruce George
    DiPaola, Robert S.
    Beckett, Yasmeen
    Bentlyewski, Edward
    Zheng, Ling
    Fang, Bruno
    Allen, Joshua
    Mehnert, Janice M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors
    Bashir, Babar
    Wang, Judy S.
    Falchook, Gerald
    Fontana, Elisa
    Arkenau, Hendrik-Tobias
    Carter, Louise
    Galot, Rachel
    Basu, Bristi
    Greystoke, Alastair
    Subbiah, Vivek
    Richardson, Debra L.
    Orr, Hanna
    Bennett, Gavin
    Sharma, Rajiv
    Xu, Hongmei
    Paganoni, Paola
    Xu, Cong
    Campbell, Carly
    McKean, Meredith
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (29)
  • [38] A First-in-Human Phase I Dose Escalation Study of IMM01, Sirpα Fc Protein in Patients with Relapsed or Refractory Lymphoma
    Qi, Junyuan
    Sun, Mingyuan
    Ji, Dongmei
    Zhou, Ping
    Xing, Shuning
    Huang, Cheng
    Lu, Qiying
    Tian, Wenzhi
    Qiu, Lugui
    BLOOD, 2022, 140 : 3651 - 3652
  • [39] A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
    Carducci, Michael A.
    Wang, Ding
    Habermehl, Christina
    Bodding, Matthias
    Rohdich, Felix
    Lignet, Floriane
    Duecker, Klaus
    Karpenko, Oleksandr
    Pudelko, Linda
    Gimmi, Claude
    LoRusso, Patricia
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (08): : 1638 - 1647
  • [40] First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors
    Sommerhalder, David
    Hamilton, Erika P.
    Mukohara, Toru
    Yonemori, Kan
    Mita, Monica M.
    Yamashita, Toshinari
    Zheng, Jenny
    Liu, Li
    Maity, Arnab K.
    Mishra, Natasha Homji
    Bogg, Orlaith
    Li, Meng
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345